

Supplementary Table 3. Median with IQR values of sCD40 and sCD40L in plasma (A.U., SUMMIT cohort) when comparing between two groups (Mann-Whitney U test)

	CD40 (n=1,438)		CD40L (n=1,438)		
	Content (A.U.)	P, adjusted*	Content (A.U.)	P, adjusted	
Female sex (vs. male sex)	9.16 (8.71-9.90) vs. 9.14 (8.70-9.89)	0.94	6.37 (5.04-8.06) vs. 6.99 (5.62-8.24)	0.0016	
Diabetes type 2 (yes vs. no)	9.18 (8.74-9.91) vs. 9.08 (8.61-9.84)	0.016	6.94 (5.48-8.27) vs. 6.52 (5.17-8.02)	0.020	
Stroke (yes vs. no)	9.75 (9.08-10.37 ) vs. 9.12 (8.70-9.80)	0.000030	7.88 (5.62-8.65) vs. 6.75 (5.37-8.16)	0.020	
Hypertension (yes vs. no)	9.24 (8.73-9.95) vs. 8.98 (8.37-9.76)	0.00021	6.86 (5.39-8.21) vs. 6.63 (5.33-8.18)	0.51	
AMI (yes vs. no)	9.27 (8.70-9.98) vs. 9.10 (8.70-9.82)	0.016	7.13 (5.47–8.24) vs. 6.71 (5.34–8.19)	0.28	

IQR, interquartile range; sCD40, soluble CD40; sCD40L, soluble CD40 ligand; A.U., arbitrary unit; SUMMIT, The SUrrogate markers for Micro- and Macro-vascular hard endpoints for Innovative diabetes Tools; AMI, acute myocardial infarction.

Supplementary Table 4. Spearman correlations between the circulating levels of sCD40 and sCD40L (A.U., SUMMIT cohort) and change in IMT in the CCA and the carotid bulb region assessed by vascular ultrasound (at the 3-year follow-up point compared to study inclusion)

		CD40			CD40L	
IMT change (mm)	(n=1,438 at inclusion; n=798 at follow-up)			(n=1,438 at inclusion; n=798 at follow-up)		
	r	Р	P, adjusted*	r	Р	P, adjusted
Right						
Mean IMT in CCA	-0.046	0.18	0.63	0.014	0.69	0.90
Max IMT in CCA	0.015	0.67	0.82	0.090	0.009	0.027
Mean IMT in bulb	0.027	0.44	0.82	0.149	0.000022	0.00011
Max IMT in bulb	0.075	0.034	0.21	0.243	$3.65 \times 10^{-12}$	2.55×10 <sup>-11</sup>
Left						
Mean IMT in CCA	-0.039	0.25	0.68	0.014	0.69	0.90
Max IMT in CCA	0.051	0.14	0.59	0.115	0.001	0.0040
Mean IMT in bulb	0.025	0.47	0.82	0.233	$1.66 \times 10^{-10}$	9.96×10 <sup>-10</sup>
Max IMT in bulb	0.092	0.009	0.070	0.261	7.86×10 <sup>-14</sup>	6.29×10 <sup>-13</sup>

sCD40, soluble CD40; sCD40L, soluble CD40 ligand; A.U., arbitrary unit; SUMMIT, The SUrrogate markers for Micro- and Macro-vascular hard endpoints for Innovative diabetes Tools; IMT, intima-media thickness; CCA, common carotid artery.

<sup>\*</sup>P-value adjusted for multiple comparisons (according to the Holm-Šídák test).

<sup>\*</sup>P-value adjusted for multiple comparisons.